GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Current Deferred Revenue

Firebrick Pharma (ASX:FRE) Current Deferred Revenue : A$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Firebrick Pharma's current deferred revenue for the quarter that ended in Jun. 2024 was A$0.00 Mil.

Firebrick Pharma Current Deferred Revenue Historical Data

The historical data trend for Firebrick Pharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Current Deferred Revenue Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Current Deferred Revenue
- - - -

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue - - - - -

Firebrick Pharma Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Current Deferred Revenue
Comparable Companies
ASX:AGH ASX:EOF ASX:EXL ASX:IVX ASX:PER ASX:RGT ASX:CAN ASX:ECS ASX:BP8 ASX:NXS LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines